智通财经APP讯， 北芯生命(688712.SH)发布2025年度业绩快报，报告期内，公司实现营业收入 54,210.81万元，较上年同期增长71.23%;归属于母公司所有者的净利润8,062.19万元，归属于母公司所有 者的扣除非经常性损益的净利润6,513.95万元，较上年同期实现扭亏为盈。 报告期内，公司核心产品凭借有显著临床价值的差异化创新，在满足过往未被完全满足的重要临床需求 方面，持续获得国内外专家的广泛认可，产品已进入全球超过60个国家和地区，在超过2,000家医院实 现临床应用。其中，海外业务营业收入同比增长超过130%，在公司收入占比进一步提升，公司国际化 业务取得快速突破。 ...

（文章来源：证券日报） 证券日报网讯 2月24日，三诺生物在互动平台回答投资者提问时表示，三诺爱看i3CGM在国际期刊 DiabetesTherapy临床数据意味着公司的临床试验设计和数据分析得到了国际一流专家的认可。三诺 CGM在临床中达到FDA提出对iCGM性能指标，对齐国际一流水平。无论是国内临床数据还是国际期刊 发表的数据，都验证了三诺CGM已具备全球竞争力。目前公司一代、二代CGM产品已在全球多个国家 和地区完成注册，并逐步开始在多个国家的医保市场和现金市场实现商业化落地。公司将以此次临床数 据验证为契机，继续扎实全球市场的拓展。后续如有重大进展，公司将严格按照相关法律法规和监管要 求，及时履行信息披露义务。 ...

自願公告 中生（蘇州）醫療科技有限公司產品 獲發馬來西亞醫療器械註冊證 本公告乃由中生北控生物科技股份有限公司（「本公司」，與其附屬公司統稱為「本 集團」）自願作出，旨在提供本公司股東及潛在投資者有關本集團之最新業務發展。 本公司董事（「董事」）會（「董事會」）欣然宣佈，本公司之附屬公司中生（蘇州）醫 療科技有限公司（「中生醫療」）自主研發之BioCyte 系列流式細胞儀，近日成功通 過馬來西亞醫療器械管理局的審核，正式獲得馬來西亞醫療器械註冊證，註冊編 號為IVDA9463526–225393。該註冊證的取得，標誌著相關產品已具備在馬來西亞 合法上市、銷售及使用的資格，也為本公司拓展東南亞市場、服務全球臨床與科研 使用者邁出了堅實有力的一步。 一、 產品基本情況 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任 何部分內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 馬來西亞對醫療器械准入設有嚴格監管標準。中生醫療依據當地相關法規要 求，完成產品檢測、技術資料提交及審核程式，最終獲得馬來西亞醫療器械管 理 ...

（文章来源：新华财经） 来源：沙利文分析 沙利文表示，中国医疗器械的研发创新能力稳步提升，NMPA批准上市的创新医疗器械数量逐年增加，中国品牌海外认知度提高等，这些因素共同推动了 中国医疗器械企业向海外市场拓展，寻求更广阔的增长空间。相比于国内市场，海外市场不仅空间广阔，细分市场的增长潜力巨大，同时新兴市场医疗需 求旺盛，为中国企业提供了差异化竞争机遇。中国医疗器械产品凭借其高性价比、创新力及品牌力升级等优势，具有较强的竞争力，中国医疗器械国际化 已成为大势所趋。 根据沙利文数据分析，2020-2024年，中国医疗器械总体市场规模已从7298亿元人民币增至9417亿元人民币，年复合增长率为6.6%。预计到2035年，中国 医疗器械总体市场规模将达到18134亿元人民币。 11月25日，全球增长咨询公司弗若斯特沙利文（Frost & Sullivan，简称"沙利文"）发布《2025中国医疗器械国际化现状与趋势蓝皮书》（简称"蓝皮 书"）。蓝皮书显示，随着人口老龄化加速，医疗需求升级及技术创新等因素，中国及全球医疗器械市场规模呈现出稳步增长态势，并将逐步释放出巨大 潜力。据沙利文数据分析，中国近年来医疗器械市场规 ...

Core Viewpoint - Mindray Medical has initiated its IPO process on the Hong Kong Stock Exchange, marking its third listing after previously entering the US and A-share markets. The primary goal of this IPO is to expand its presence in international markets, especially in light of slowing domestic growth and increasing competition from domestic rivals like United Imaging [2][3][4]. Company Overview - Mindray Medical's revenue and net profit for the first three quarters of 2025 were 25.834 billion and 7.570 billion respectively, showing declines of 12.38% and 28.83% year-on-year [8]. - The company has faced challenges due to a slowdown in the domestic medical device market, exacerbated by longer income confirmation cycles following public tenders [10][9]. Market Competition - Mindray Medical's core business segments include in-vitro diagnostics, life information and support, medical imaging, and emerging sectors, where it holds the top position in the domestic market. However, it is now facing intensified competition, particularly in the ultrasound segment from United Imaging, which has recently launched several ultrasound products [12][15][16]. International Expansion Strategy - The IPO is not primarily for financing but aims to enhance Mindray's international brand recognition. The company reported a more than 10% year-on-year growth in international business, with the European market growing over 20% [19][20]. - Mindray's strategy for mature markets focuses on product performance and innovation, while for emerging markets, it emphasizes high-cost performance products to increase market penetration [21][22]. Acquisition Plans - Mindray Medical has a history of successful acquisitions, having completed several between 2021 and 2024 to expand its in-vitro diagnostics and electrophysiology businesses. The company aims to explore potential global acquisition opportunities through this IPO [24][25][26]. Valuation Challenges - Despite its strong market position, Mindray Medical has seen its market value decrease by nearly 20% this year, which may impact its IPO valuation. The current market environment for IPOs in Hong Kong has been challenging, with other companies facing similar issues [5][27].

Core Viewpoint - Mindray Medical is intensifying its internationalization strategy by applying for a listing of overseas-listed foreign shares on the Hong Kong Stock Exchange, aiming to enhance global R&D and sales capabilities [1][6]. Group 1: Internationalization Strategy - The primary goal of the Hong Kong listing is to establish an international capital platform to support the company's global strategy [1]. - As of the first three quarters of 2025, international business accounted for over half of the company's total revenue, indicating a significant shift towards global markets [1][7]. - Mindray Medical's international revenue is expected to continue growing, particularly in developing countries, with a focus on high-end customers [7]. Group 2: Financial Health - As of September 2025, the company reported cash reserves of 171.3 billion yuan, with total liabilities of 150.2 billion yuan, resulting in a low debt-to-asset ratio of 25.34% [1][6]. - The company has not engaged in any refinancing since its A-share listing in 2018 and has maintained a high dividend payout ratio, with cumulative cash dividends reaching 337 billion yuan [4][5]. Group 3: Historical Context - This IPO marks Mindray Medical's third listing, following its successful debut on the New York Stock Exchange in 2006 and its return to the A-share market in 2018 [3]. - The company has a strong market position, with its 2024 revenue projected to exceed that of the combined major domestic competitors, and it holds leading market shares in multiple product categories [2].

Core Viewpoint - The article discusses the upcoming IPO of Mindray Medical, highlighting its historical significance and growth trajectory in the high-end medical device market in China [5][12]. Company History - Mindray Medical was founded in 1991 by three colleagues, including Li Xiting, who left high-paying jobs to start the company, marking the beginning of China's high-end medical device industry [7][8]. - The company initially faced funding challenges but secured its first venture capital investment of $2 million in 1997, which helped it stabilize and grow [9]. - Mindray became the first Chinese medical device company to list overseas, successfully going public on the New York Stock Exchange in 2006 [11]. IPO and Market Performance - Mindray's IPO on the Shenzhen Stock Exchange in 2018 raised nearly 6 billion yuan, setting a record for the largest IPO on the ChiNext board that year [12]. - The company's market capitalization peaked at over 320 billion yuan during the surge in demand for medical devices in 2020, although it has since adjusted to a current market cap of over 270 billion yuan [12]. Strategic Goals - The upcoming listing on the Hong Kong Stock Exchange is part of Mindray's strategy to enhance its global business and capital presence, with a goal to increase international revenue to over 70% [12]. - The company aims to rank among the top ten global medical device companies by 2030, reflecting its ambition for international expansion [12].

Core Insights - The National Medical Products Administration (NMPA) is enhancing the legal and standard system for medical devices, increasing support for R&D innovation, and improving review and approval efficiency to promote high-quality development in the medical device industry [1] Industry Developments - In the first eight months of this year, Beijing's exports of medical instruments and devices reached 5.83 billion yuan, a year-on-year increase of 21.5% [1] - The overseas market for medical devices is significantly larger than the domestic market, leading to high growth for many companies in international business [1] Innovation and Product Approvals - Under supportive policies, there has been a surge in innovative product approvals in the medical device sector [2] - David Medical's subsidiary received a registration certificate for a disposable endoscopic linear cutting stapler, enhancing the company's product line and core competitiveness [2] - The NMPA approved a new "Extended Depth of Focus Intraocular Lens" from Tianjin Century Kangtai Biomedical Engineering Co., which aims to improve vision correction post-cataract surgery [2] High-End Medical Imaging Equipment - Neusoft Medical's X-ray computed tomography device received approval, featuring higher spatial resolution and multiple energy imaging capabilities [3][4] - The NMPA is actively supporting the innovation of high-end medical devices, including photon-counting CT technology, which represents a significant advancement in imaging [4][5] Company Performance - Weili Medical reported a third-quarter revenue of 446 million yuan, a year-on-year increase of 16.09%, with a net profit of 70.57 million yuan, up 16.31% [6] - Xiangsheng Medical's revenue for the first three quarters was 343 million yuan, a decrease of 5.3%, while its net profit showed a slight decline [6] - Mindray Medical anticipates positive growth in its third-quarter revenue, with international business expected to accelerate [7] International Expansion - Companies are increasingly focusing on internationalization, with Mindray Medical planning to issue H-shares to enhance its global capital operations [8] - Weili Medical is constructing a factory in Indonesia, expected to start shipments by the end of Q1 2026, primarily supplying products to major clients in the U.S. [9] - The international business of medical device companies is projected to surpass domestic business in the future, with many companies transitioning from imitation to leading global innovation [10]

Core Insights - The National Medical Products Administration (NMPA) is enhancing the legal and standard system for medical devices, increasing support for R&D innovation, and improving review and approval efficiency to promote high-quality development in the medical device industry [1] Industry Overview - In the first eight months of this year, Beijing's exports of medical instruments and devices reached 5.83 billion yuan, marking a year-on-year increase of 21.5% [1] - Analysts believe that the overseas market for medical devices is several times larger than the domestic market, leading to significant growth in international business for many medical device companies [1] - The valuation of companies recognized for their international capabilities is also increasing [1] Company Focus: Mindray Medical - Mindray Medical's overseas revenue proportion reached 50% in the first half of 2025, becoming a core growth engine for the company, up from 40% in 2021 [1] - The increase in international revenue is attributed to the company's sustained investments in overseas channels, R&D, and acquisitions [1] - Mindray Medical currently operates 64 subsidiaries and 5 R&D centers overseas, with products entering 80 of the top 100 hospitals globally [2] Strategic Acquisitions - In 2021, Mindray Medical acquired Finland's HyTest to address upstream material supply issues and enhance the quality of IVD consumables [2] - In 2023, the acquisition of Germany's DiaSys further deepened Mindray's IVD business layout and improved its overseas supply chain [2] Market Position - Mindray Medical has entered the global top 30 medical device companies, with several product lines ranking in the top three globally, and nearly half of its revenue coming from international business [2] - The growth momentum for the industry is shifting towards international business and technological innovation, with expectations that the international business share will surpass domestic business in the future [2]

Core Insights - The National Medical Products Administration (NMPA) is enhancing the legal and standard system for medical devices, increasing support for R&D innovation, and improving review and approval efficiency to promote high-quality development in the medical device industry [1] Group 1: Market Performance - In the first eight months of this year, Beijing's medical instruments and devices exports reached 5.83 billion, a year-on-year increase of 21.5% [1] - Some medical device companies have reported strong Q3 performance, with Weili Medical achieving a Q3 revenue of 446 million, up 16.09% year-on-year [5] - Xiamen Medical reported a revenue of 343 million in the first three quarters, a decrease of 5.3% year-on-year, while its Q3 net profit increased by 41.95% [6] Group 2: Innovation and Product Development - Under supportive policies, Chinese medical device companies are experiencing a surge in innovation, with multiple new products receiving approval [2] - David Medical's subsidiary received a registration certificate for a new type of surgical stapler, enhancing the company's product line and competitiveness [2] - Neusoft Medical's X-ray CT device received approval, offering higher spatial resolution and better clinical imaging capabilities compared to traditional CT [3] Group 3: International Expansion - Companies are increasingly focusing on international markets, with Mindray Medical planning to issue H-shares to enhance its global capital operations [7] - Weili Medical is constructing a factory in Indonesia, expected to start shipments in Q1 2026, primarily supplying products to major US clients [8] - Analysts believe that the international business potential is vast, with many companies experiencing high growth in overseas markets [8]